Health · 27 views
Patient Death Reported in Multiple Sclerosis CAR-T Study
(MedPage Today) -- The investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy zolacabtagene autoleucel (zola-cel) showed the potential to treat people with highly active relapsing multiple sclerosis (MS) and…
AI Summary
Zolacabtagene autoleucel, an investigational CD19‑directed CAR‑T cell therapy, demonstrated potential for treating patients with highly active relapsing multiple sclerosis and progressive multiple sclerosis.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Single blood protein stands out among 30 tests for assessing fatty liver diseaseContinue reading
- Do you know signs of a stroke? BE FAST are the words to rememberContinue reading
- Tumor index can identify breast cancer patients' drug responseContinue reading
- 'They're Looking for Scapegoats': What We Heard This WeekContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow